EA at Outperform Rating, Teradyne at Buy Rating, Biogen an Overweight
Electronic Arts Inc. (NASDAQ:EA): BMO Capital believes that shares of Electronic Arts have dropped due to worries over the company’s Star Wars: The Old Republic game, but the firm thinks that the game will drive significant profits and it reiterates an Outperform rating.
Teradyne Inc. (NYSE:TER): DA Davidson expects Teradyne’s Q4 results to mark a bottom for the company. The firm predicts that Teradyne’s Q1 guidance will exceed expectations, and it reiterates a $20 target and Buy rating.
Biogen Idec Inc. (NASDAQ:BIIB): Piper Jaffray believes peak sales of Tysabi could reach $4B-$5B after the FDA approved the Stratify JCV Antibody ELISA test to help patients determine their risk of developing PML when taking Tysabri. The firm reiterates an Overweight rating on shares of Biogen with a $136 price target.
Medivation, Inc. (NASDAQ:MDVN): Summer Street believes Medivation’s AFFIRM trial has a high chance for a positive safety profile. The firm raised its price target for the stock and reiterates a Buy rating on the name.
Euronet Worldwide Inc. (NASDAQ:EEFT): Wells Fargo attributes the sell-off in shares Euronet to the discovery of a www.securelist.com story that said that there was a security breach in Europe and that Euronet may be the source. Wells Fargo does not believe this will be a major issue, and said it spoke to Euronet and the company plans to issue a release shortly explaining what happened. Wells views the situation as very manageable for Euronet and thinks today’s sell-off is overdone.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.